3 January 2025 in JNCI Cancer Spectrum
Background: Obesity, classified by body mass index (BMI), is associated with higher postmenopausal breast cancer (BCa) risk. Yet, the associations between abdominal visceral (VAT) and subcutaneous adipose tissue (SAT) with BCa are unclear. Methods: We assessed BCa associations with abdominal VAT and SAT in a prospective cohort of postmenopausal women without a history of cancer and with 27 years follow-up (N = 9950), during which all new cancers were adjudicated. Dual-energy x-ray absorptiometry scans assessed adiposity at baseline, year 3, and year 6. Competing-risks multivariable sub-hazard ratios (SHR), with adjustments for sociodemographic, behavioral, reproductive, and anthropometric characteristics, were estimated for baseline and time-dependent associations between VAT, SAT, and incident BCa. Results: Participants averaged 63.3 ± 7.4 years of age and a BMI of 28.20 ± 5.72 kg/m2 at baseline. The models included 738 incident BCa case patients (N = 593 invasive; N = 145 in situ). Baseline VAT and SAT area were associated with statistically significantly increased BCa risk, by 36% and 19%, respectively. Increasing VAT/SAT ratio was associated with an 8% increase in incident BCa. Time-dependent models produced similar results. VAT and VAT/SAT associated BCa risk was highest for African American/Black women, although not statistically significantly different from other groups. Quartiles (Q) of VAT/SAT were also explored; the SHR for Q4 compared with Q1 was 1.49 (95% CI = 1.18 to 1.87). Conclusion: Higher abdominal VAT and SAT are associated with an increased risk of postmenopausal BCa, and VAT/SAT may provide a distinctive risk estimate. Potential racial and ethnic differences require replication in a larger sample (Women’s Health Initiative; NCT00000611; https://clinicaltrials.gov/study/NCT00000611).
19 May 2025 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Background: The association of metformin with mortality has been mixed, and no prior study has determined whether metformin initiation is associated with exceptional longevity, defined as survival to ages 90 and older. Methods: We performed a new-user, active comparator cohort study using the target trial emulation framework among the Women’s Health Initiative cohort to determine whether metformin versus sulfonylurea initiation was associated with exceptional longevity (survival to age 90). We identified participants ≥60 years with incident type 2 diabetes and no history of hypoglycemic agents or insulin prior to treatment initiation to perform intention-to-treat analyses. We used 1:1 propensity score matching on demographic characteristics, lifestyle behaviors, diabetes duration, comorbidities (hypertension, cardiovascular disease, chronic obstructive pulmonary disease, and cancer), body mass index, and concomitant medications to balance treatment groups on key confounders. Results: Among 438 propensity score-matched women with type 2 diabetes, the incidence rate of death before age 90 per 100 person-years in women initiating metformin monotherapy was 3.7 (95% CI: 3.1–4.4) compared with 5.0 (95% CI: 4.2–5.8) for sulfonylurea monotherapy. The adjusted risk of death before age 90 was 30% lower for initiation of metformin monotherapy versus sulfonylurea monotherapy (hazard ratio, 0.70; 95% CI: 0.56–0.88). Conclusions: In this first target trial emulation of metformin and exceptional longevity, we found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. Because this comparison was not made to placebo in a randomized controlled trial and given the observational design with potential for residual confounding, causality cannot be inferred.
4 March 2025 in JMIR Cancer
Background: Though telehealth has been a promising avenue for engaging cancer survivors with health care and lifestyle programming, older and rural-dwelling cancer survivors may have additional challenges in accessing digital devices and tools that have not yet been described. This study aimed to use a robust, nationally representative sample collected in 2022 to provide an updated view of digital technology use and the use of technology for health in this population. Objective: This study aimed to examine the prevalence of digital technology use for health-related activities among older cancer survivors in both rural and urban settings. The primary outcomes of interest included (1) internet access and use for health-related activities, (2) digital device ownership and use as a tool for health behaviors, (3) use of social media for health, and (4) use of telehealth. Methods: A cross-sectional analysis of the National Cancer Institute’s Health Information National Trends Survey Cycle 6 (HINTS 6) was completed to examine the prevalence of digital technology use among older cancer survivors. For analysis, the sample was restricted to cancer survivors over the age of 60 years (n=710). Unadjusted and adjusted logistic regression models were used to test the association between rurality and digital health tool use. Results: Overall, 17% (125/710) of the sample lived in a rural area of the United States and the mean sample age was 73 (SD 8.2) years. Older cancer survivors, regardless of rural-urban status, reported a high prevalence of internet usage (n=553, 79.9%), digital device ownership (n=676, 94.9%), and social media use (n=448, 66.6%). In unadjusted models, rural survivors were less likely than urban survivors to report that they had used a health or wellness application in the previous year (odds ratio [OR] 0.56, 95% CI 0.32-0.97; P=.04). In adjusted models, rural survivors were more likely to report that they had shared personal health information on social media (OR 2.64, 95% CI 1.13-6.19; P=.03). There were no differences in the proportion of rural and urban respondents who reported receiving health services through telehealth in the previous year. Conclusions: Regardless of the residential status, older cancer survivors report high internet and technology use for health-related activities. These results show promise for the feasibility of using digital technologies to implement supportive care and wellness programming with older cancer survivors.
1 August 2025 in Cancer Epidemiology, Biomarkers & Prevention
Background: Determine if dual-energy X-ray absorptiometry (DXA)–derived adiposity was associated with colorectal cancer incidence and mortality in postmenopausal women from the Women’s Health Initiative DXA cohort. Methods: Whole-body DXA scans estimated adiposity. Women with a history of cancer (except nonmelanoma skin cancer) or missing baseline DXA were excluded. For 27 years of follow-up, outcomes and deaths were adjudicated. Descriptive statistics by colorectal cancer status were calculated. Fine and Gray’s competing risks regression was used to estimate sub-HRs and 95% confidence intervals. Observation time was from enrollment to the first colorectal cancer event or competing risk (other cancer, other cause of death); women without cancer at the last follow-up were censored. Covariates included sociodemographic, clinical, and study characteristics. Results: After exclusions, 9,950 women were included, with 191 first-incident colorectal cancer cases and 88 colorectal cancer–related deaths identified. At baseline, the mean (±SD) age was 63.3 (±7.4) years, and the body mass index (BMI) was 28.2 (±5.7) kg/m2. In adjusted models, baseline continuous abdominal visceral adipose tissue (VAT; per 100 cm2) and android fat (per kg) were significantly associated with a higher risk of first-incident colorectal cancer: sub-HRs (95% confidence interval) were 1.23 (1.04–1.45) and 1.15 (1.01–1.31), respectively. There were no significant associations between adiposity and colorectal cancer mortality. Conclusions: Higher amounts of abdominal VAT and android fat were associated with a higher risk of colorectal cancer incidence in postmenopausal women. Impact: Associations between VAT and colorectal cancer, independent of BMI, support the clinical assessment of body composition across weight categories. A head-to-head comparison of VAT and BMI for colorectal cancer prediction is recommended in future research.